APA
Kastritis E., Gavriatopoulou M., Dimopoulos M. A., Eleutherakis-Papaiakovou E., Kanellias N., Roussou M., Pamboucas C., Toumanidis S. T. & Terpos E. (20160125). Osteoprotegerin is a significant prognostic factor for overall survival in patients with primary systemic amyloidosis independent of the Mayo staging. : Blood cancer journal.
Chicago
Kastritis E, Gavriatopoulou M, Dimopoulos M A, Eleutherakis-Papaiakovou E, Kanellias N, Roussou M, Pamboucas C, Toumanidis S T and Terpos E. 20160125. Osteoprotegerin is a significant prognostic factor for overall survival in patients with primary systemic amyloidosis independent of the Mayo staging. : Blood cancer journal.
Harvard
Kastritis E., Gavriatopoulou M., Dimopoulos M. A., Eleutherakis-Papaiakovou E., Kanellias N., Roussou M., Pamboucas C., Toumanidis S. T. and Terpos E. (20160125). Osteoprotegerin is a significant prognostic factor for overall survival in patients with primary systemic amyloidosis independent of the Mayo staging. : Blood cancer journal.
MLA
Kastritis E, Gavriatopoulou M, Dimopoulos M A, Eleutherakis-Papaiakovou E, Kanellias N, Roussou M, Pamboucas C, Toumanidis S T and Terpos E. Osteoprotegerin is a significant prognostic factor for overall survival in patients with primary systemic amyloidosis independent of the Mayo staging. : Blood cancer journal. 20160125.